New Horizons in the
Management of Sickle Cell Disease (SCD): Leveraging Treatment
Breakthroughs to Make Informed Decisions in Managed Care
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of Sickle Cell Disease
These are archives of live webinars held between December 4 to
December 17, 2020.
If you participated in any of the live webinars, you are not
eligible to
claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all 3 or in order.
These activities are valid from January 1, 2020 to January 1, 2023
This
series is supported by educational grants from
Global Blood Therapeutics and Novartis
Audience:
This activity is intended for healthcare professionals practicing in managed
care environments.
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
certificate.
Description:
Sickle cell disease (SCD) is a chronic, life-long,
debilitating disease with many forms that can range in clinical severity from
asymptomatic to life-threatening. In the US, SCD affects an estimated 90,000 to
100,000 Americans. This disease can lead to the obstruction of blood vessels,
reduced blood flow to vital organs, and a weakened immune system. Fortunately
for patients, novel therapies have been approved that have shown tremendous
benefit in SCD. |
A Deeper Look into New Therapies in the Management of Sickle
Cell Disease: How the Latest Advances May Impact Decision-Making
- Discuss the pathophysiology, physical manifestations, economic burden,
clinical course, and impact on patient quality of life of sickle cell
disease (SCD)
- Examine the mechanisms underlying new and emerging treatments for
patients with SCD that work upstream of sickle hemoglobin (HbS)
polymerization and may be disease-modifying
- Evaluate the latest clinical evidence regarding new and emerging
disease-modifying options for patients with SCD and the implications for
patients
- Analyze the safety and efficacy of new therapies that manage acute vaso-occlusive
pain events in SCD
- Examine the latest understanding regarding SCD phenotypes and
implications for treatment selection and sequencing
- Identify patients with vaso-occlusive pain events in SCD for whom a
newer therapy is an appropriate choice for the next step in the management
of their disease
Physician, Nursing and CMCN credits valid to
January 1, 2022 |